Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study
Cancer Medicine · 2023
DOI: 10.1002/cam4.6455 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Jie Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-Oncology, Chongqing University Cancer Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Thromboembolism. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Natural Science Foundation, Decision-making consultation and management innovation project in the Shapingba District of Chongqing.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have emerged as a standard treatment for various malignancies. However, research indicates blocking the immune checkpoint pathway may exacerbate atherosclerotic lesions.
Objectives
We aimed to investigate whether ICI therapy increases the risk of arterial thromboembolic events (ATEs).
Methods
A retrospective cohort study was conducted on patients with histologically confirmed cancer at our institution between 2018 and 2021, using the propensity score matching method. The primary endpoint was ATEs occurrence, comprising acute coronary syndrome, stroke/transient ischemic attack, and peripheral arterial thromboembolism. Subgroup analyses assessed whether the ICI treatment effect on ATEs varied over time by limiting the maximum follow‐up duration. Logistic regression analysis identified ATE risk factors in ICI‐treated patients.
Results
Overall, the ICI group ( n = 2877) demonstrated an ATEs risk 2.01 times higher than the non‐ICI group (RR, 2.01 [95% CI (1.61–2.51)]; p < 0.001). Subgroup analysis revealed no significant increase in ATEs risk for ICI‐treated patients within 1 year (Limited to a max 9‐month follow‐up, p = 0.075). However, ATEs risk in the ICI group rose by 41% at 1 year ( p = 0.010) and 97% at 4 years ( p ≤ 0.001). Age, diabetes, hypertension, peripheral atherosclerosis, atrial fibrillation, chronic ischemic heart disease, distant cancer metastasis, and ICI treatment cycles contributed to ATEs risk elevation in ICI‐treated patients.
Conclusion
ICI‐treated patients may exhibit a higher risk of ATEs, especially after 1 year of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardio-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
- School of Medicine, Chongqing University, Chongqing, China.
- Medical Record Management Department, Chongqing University Cancer Hospital, Chongqing, China.
- Chongqing Cancer Multi-Omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Förderung
- Chongqing Natural Science Foundation
- Decision-making consultation and management innovation project in the Shapingba District of Chongqing
Zitieren
APA
Zhu, J., Chen, Y., Zhang, Y., Wang, W., Wang, Y., Lu, Z., Zhang, Y., Lei, H., Li, D., Long, B., & Liu, H. (2023). Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.6455
Vancouver
Zhu J, Chen Y, Zhang Y, Wang W, Wang Y, Lu Z, et al. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Medicine. 2023. doi:10.1002/cam4.6455
BibTeX
@article{Zhu2023,
author = {Zhu, Jie and Chen, Yue and Zhang, Yuanlong and Wang, Wei and Wang, Yujue and Lu, Zhuo and Zhang, Yulin and Lei, Haike and Li, Dairong and Long, Bo and Liu, Haixia},
title = {Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6455}
}
EUVIMED